Remove Biosimilars Remove Communication Remove Drug Development
article thumbnail

Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in

Pharmaceutical Technology

Robert Barrie June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Bayer’s Eylea is a heavyweight of the ophthalmic drug landscape, approved for a range of eye diseases. Go deeper with GlobalData Reports LOA and PTSR Model - Aflibercept Biosimilar in Age Related Macular. CucuMberStudio via Shutterstock.

article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

CMS should draw on lessons from previous transitions, including biosimilar coverage rollouts and site-of-care policy shifts, to avoid known implementation pitfalls. Even well-intentioned policies can create access disparities if communication and operational support are lacking.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

More Uncertainty and Less Advice from FDA Means Companies will Need to Even More Carefully Chart their own Course to Achieve their Goals

FDA Law Blog: Biosimilars

A less robust schedule of external meetings and slower pace of publications of Guidance to Industry may further slow communication to sponsors who eagerly await information critical to inform their development programs. Just as important will be the need to respond expertly, efficiently and meaningfully to FDA concerns.

article thumbnail

Pharmacist to Clinical Strategy Leader: Brendan Doran on Building a Career in Biotech

The Nontraditional Pharmacist

The last time we spoke, biosimilars were this new thing and everyone was trying to figure out what was going to happen regulatory-wise and a lot of other changes since then. I think my daughter was just barely one. Now she’s seven going into second grade. And then I think USP 797 was finally updated and that was a long time coming.

article thumbnail

Asian Pharma Stocks Dropping As US Cuts Drug Prices

Pharma Marketing Network

companies rely on active pharmaceutical ingredient (API) manufacturing and biosimilar development from partners in India, China, and South Korea. regulators pushing for reshoring or nearshoring critical drug manufacturing, Asian suppliers may face fewer contracts and greater scrutiny. Supply Chain Tightening With U.S.

article thumbnail

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Industry reactions have been mixed.

article thumbnail

CDMO insights podcast series: Our Experience is Your Strength | Episode #1 Formulation

Pharmaceutical Technology

July 7, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The early stages of formulation development and analytical testing can be some of the most exciting phases of drug development, fueled by the anticipation that follows the discovery of a promising new active pharmaceutical ingredient (API) or combination.